References
- Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-7
- Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
- Briggs A, Claxton K, Sculpher M. Decision Modeling for Health Economic Evaluation. UK: Oxford University Press, 2008
- Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost effectiveness analysis. Pharmacoeconomics 2006;24:1-19
- ISPOR. Country specific pharmacoeconomic guidelines, ISPOR 2006. Available at: http://www.ispor.org/PEguidelines/index.asp. Last accessed 29 Sept 2014
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
- Alagoz O, Hsu H, Schaefer AJ, et al. Markov decision processes: a tool for sequential decision making under uncertainty. Med Decis Making 2010;30:474-83
- Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? PharmacoEconomics – Italian Res Articles 2004;6:121-30
- Baron R, Schwittay A, Binder A, et al. Effectiveness of tapentadol prolonged release (PR) versus oxycodone/naloxone PR for severe chronic low back pain with a neuropathic pain component. Poster presented at Pain Week 2014, 2–6 September 2014, Las Vegas, NV, USA
- Binder A, Baron R, Schwittay A, et al. Safety and tolerability of tapentadol prolonged release (PR) versus oxycodone/naloxone PR for severe chronic low back pain with a neuropathic pain component. Poster presented at Pain Week 2014, 2–6 September 2014, Las Vegas, NV, USA
- Schwittay A, Baron R, Binder A, et al. Effects of tapentadol prolonged release (PR) versus oxycodone/naloxone PR on quality of life and function measures in patients with severe chronic low back pain with a neuropathic pain component. Poster presented at Pain Week 2014, 2–6 September 2014, Las Vegas, NV, USA